SOURCE: MediciGlobal

MediciGlobal

February 11, 2015 13:23 ET

Meniere's Disease Team on Facebook Becomes the Largest Online Patient Community Committed to Advancing New Medical Treatments

More Than 15,000 Fans and Over 35,000 Visitors Weekly Engage With Meniere's Disease Team Page on Facebook

PHILADELPHIA, PA and LONDON, UNITED KINGDOM--(Marketwired - Feb 11, 2015) - MediciGlobal Ltd. announced today that over 15,000 Meniere's disease fans have shown their support for clinical research by joining the Facebook page Meniere's Disease Team. The community supports research efforts aimed at improving treatment options for Meniere's disease.

"We are a Facebook community dedicated to informing people with Meniere's disease about clinical research opportunities, supporting research centers conducting clinical trials, and providing information about new technologies and medical advances," said Liz Moench, president and CEO of MediciGlobal, a company dedicated to informing patients and their families about clinical research opportunities, and administrators of Meniere's Disease Team. "Importantly, Meniere's Disease Team enables us to provide our fans with an opportunity to contribute to the potential development of important new treatments for Meniere's disease, and hopefully control their disease." Recently, Meniere's Disease Team played an important role in generating awareness about a clinical research opportunity and helping to accelerate clinical trial enrollment. 

According to Dr. Kenneth S. Maxwell at Piedmont Ear Nose and Throat Associates (PENTA) in North Carolina, USA, "Studying new drug treatments designed specifically for this inner ear disorder is essential. Only through clinical trials can we advance new treatment options and provide hope for patients suffering from this terrible condition. Additionally, getting the word out about our involvement in clinical research in conjunction with Meniere's Disease Team highlights the important role social media is playing in informing patients about research opportunities."

Moench added that many published articles show that people -- including those with Meniere's disease -- are unaware of clinical trials; what to expect and where to go for more information. On the Meniere's Disease Team Facebook page, patients and caregivers are invited to sign up to be notified for future research studies at: https://www.Facebook.com/MenieresDisease

Currently, visitors to the Facebook page number over 2 million weekly. Importantly, these visitors span more than 20 countries, with the U.S., U.K., Canada, Australia, Brazil, Italy, Mexico, India and Ireland representing the countries with the most visitors.

About Meniere's Disease
Meniere's disease is an inner ear disorder that affects approximately 600,000 people in the United States. It is a disabling disorder resulting in repeated violent attacks of dizziness, ringing in the ear [tinnitus] and hearing loss that can last for hours and can ultimately cause permanent deafness in the affected ear. It is likened to stepping off a merry-go-round and the disorienting spinning sensation that causes one to be off balance and nauseous. However, unlike the effects of the merry-go-round that lasts only minutes, Meniere's disease episodes can last for days. As a result, people with Meniere's disease are often unable to work, drive, interact with family or enjoy life. Furthermore, since these episodes are unpredictable, anxiety and loss of confidence or independence often occurs.

About MediciGlobal
MediciGlobal is in the business of making a meaningful difference to patient health -- by identifying and engaging patients for clinical trials and by building deep and lasting connections with its many stakeholders: patients, researchers and pharmaceutical sponsors. MediciGlobal's clinical trial recruitment practices are guided by global standards and by a concern for the lives of the patients who put their trust in the MediciGlobal team. MediciGlobal makes certain that those who participate in clinical trials fully understand what clinical trial participation means, and that their participation is guarded by strict privacy policies. MediciGlobal is an industry leader in the use of social media and internet-based technologies to connect with patients and physicians to advance clinical trials. Its more than 40 Facebook communities exceed 1 million fans and more than 12 million visitors weekly. MediciGlobal meets BBB OnLine® and WBENC accreditation standards and is certified as a Safe Harbor company.

Visit www.MediciGlobal.com to learn more.

Contact Information

  • For press inquiries please contact:

    U.S. media contacts:
    Liz Moench
    +1-610-659-5093

    Courtney Hollinger
    +1-484-674 6800

    Outside the U.S. media contact:
    Elizabeth Puller
    +44 (0)208 834 1447
    Email: Email Contact